{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:26:29Z","timestamp":1762889189830,"version":"3.45.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"DOI":"10.7759\/cureus.96593","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:22:21Z","timestamp":1762888941000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the Beneficial Effect of Empagliflozin in Reducing Hospitalisation for Heart Failure in Patients With Type 2 Diabetes Mellitus: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Akanksha","family":"Soni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olabisi P","family":"Lawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Japheth O","family":"Oyovwi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Happiness I","family":"Olaniyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wonderful O","family":"Anosike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enibokun  T","family":"Orobator","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazeem","family":"Gabriels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibad Ali Khan","family":"Ghori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliyu O","family":"Olaniyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"IDF diabetes atlas","author":"Magliano D","year":"2021","unstructured":"Magliano D, Boyko EJ. IDF diabetes atlas. International Diabetes Federation: Brussels. 2021,","journal-title":"International Diabetes Federation: Brussels"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000000691","article-title":"Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update","volume":"140","author":"Dunlay SM","year":"2019","unstructured":"Dunlay SM, Givertz MM, Aguilar D, et al.. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update. Circulation. 2019, 140:e294-e324. 10.1161\/cir.0000000000000691","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani A","year":"2018","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, et al.. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018, 379:633-44. 10.1056\/nejmoa1800256","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovi\u0107 PM","year":"2018","unstructured":"Seferovi\u0107 PM, Petrie MC, Filippatos GS, et al.. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018, 20:853-72. 10.1002\/ejhf.1170","journal-title":"Eur J Heart Fail"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/nejmoa1504720","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.124.069217","article-title":"Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: insights from the EMPACT-MI trial","volume":"149","author":"Hernandez AF","year":"2024","unstructured":"Hernandez AF, Udell JA, Jones WS, et al.. Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: insights from the EMPACT-MI trial. Circulation. 2024, 149:1627-38. 10.1161\/circulationaha.124.069217","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3548","article-title":"Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: a pre\u2010specified analysis of the EMPACT\u2010MI trial","volume":"27","author":"Petrie MC","year":"2025","unstructured":"Petrie MC, Udell JA, Anker SD, et al.. Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: a pre\u2010specified analysis of the EMPACT\u2010MI trial. Eur J Heart Fail. 2025, 27:577-88. 10.1002\/ejhf.3548","journal-title":"Eur J Heart Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02756-y","article-title":"Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial","volume":"24","author":"Ovchinnikov A","year":"2025","unstructured":"Ovchinnikov A, Potekhina A, Filatova A, Svirida O, Zherebchikova K, Ageev F, Belyavskiy E. Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial. Cardiovasc Diabetol. 2025, 24:196. 10.1186\/s12933-025-02756-y","journal-title":"Cardiovasc Diabetol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/nejmoa2022190","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021, 385:1451-61. 10.1056\/nejmoa2107038","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial","volume":"143","author":"Packer M","year":"2021","unstructured":"Packer M, Anker SD, Butler J, et al.. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial. Circulation. 2021, 143:326-36. 10.1161\/circulationaha.120.051783","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.118.039177","article-title":"Empagliflozin and the risk of heart failure hospitalization in routine clinical care: a first analysis from the EMPRISE study","volume":"139","author":"Patorno E","year":"2019","unstructured":"Patorno E, Pawar A, Franklin JM, et al.. Empagliflozin and the risk of heart failure hospitalization in routine clinical care: a first analysis from the EMPRISE study. Circulation. 2019, 139:2822-30. 10.1161\/circulationaha.118.039177","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler J","year":"2022","unstructured":"Butler J, Packer M, Filippatos G, et al.. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J. 2022, 43:416-24. 10.1093\/eurheartj\/ehab798","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.18332\/popmed\/143831","article-title":"Conducting comprehensive scoping reviews to systematically capture the landscape of a subject matter","volume":"3","author":"Kazi MR","year":"2021","unstructured":"Kazi MR, Chowdhury N, Chowdhury M, Turin TC. Conducting comprehensive scoping reviews to systematically capture the landscape of a subject matter. Popul Med. 2021, 3:36. 10.18332\/popmed\/143831","journal-title":"Popul Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6947-7-16","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical questions","volume":"7","author":"Schardt C","year":"2007","unstructured":"Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007, 7:16. 10.1186\/1472-6947-7-16","journal-title":"BMC Med Inform Decis Mak"},{"key":"ref16","article-title":"","year":"2019","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (ed). Wiley-Blackwell, Hoboken, NJ; 2019. https:\/\/onlinelibrary.wiley.com\/doi\/chapter-epub\/10.1002\/9781119536604.fmatter."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"4898","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 4898:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"71","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 71:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.90150","article-title":"Empagliflozin and cardiovascular outcomes: a systematic review of randomized controlled trials in populations with diabetes and heart failure","volume":"17","author":"Ansar F","year":"2025","unstructured":"Ansar F, Azzam A, Zafar U, et al.. Empagliflozin and cardiovascular outcomes: a systematic review of randomized controlled trials in populations with diabetes and heart failure. Cureus. 2025, 17:e90150. 10.7759\/cureus.90150","journal-title":"Cureus"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00aetrial","volume":"37","author":"Fitchett D","year":"2016","unstructured":"Fitchett D, Zinman B, Wanner C, et al.. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00aetrial. Eur Heart J. 2016, 37:1526-34. 10.1093\/eurheartj\/ehv728","journal-title":"Eur Heart J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Empagliflozin in patients with heart failure and a reduced ejection fraction","volume":"383","author":"Anker SD","year":"2020","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in patients with heart failure and a reduced ejection fraction. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32590-x","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker TA","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al.. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019, 393:31-9. 10.1016\/s0140-6736(18)32590-x","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co\u2010transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA\u2010HF)","volume":"21","author":"McMurray JJV","year":"2019","unstructured":"McMurray JJV, DeMets DL, Inzucchi SE, et al.. A trial to evaluate the effect of the sodium-glucose co\u2010transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA\u2010HF). Eur J Heart Fail. 2019, 21:665-75. 10.1002\/ejhf.1432","journal-title":"Eur J Heart Fail"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma S","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018, 61:2108-17. 10.1007\/s00125-018-4670-7","journal-title":"Diabetologia"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.36628\/ijhf.2022.0030","article-title":"SGLT-2 inhibitors in heart failure: a review of current evidence","volume":"5","author":"Talha KM","year":"2023","unstructured":"Talha KM, Anker SD, Butler J. SGLT-2 inhibitors in heart failure: a review of current evidence. Int J Heart Fail. 2023, 5:82-90. 10.36628\/ijhf.2022.0030","journal-title":"Int J Heart Fail"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini E","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis. Diabetes Care. 2016, 39:1108-14. 10.2337\/dc16-0330","journal-title":"Diabetes Care"},{"key":"ref27","unstructured":"Beyond Diabetes. The Impact of Empagliflozin in Heart Failure with Reduced Ejection Fraction. (2021). Accessed: June 19, 2025: https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2021\/03\/24\/12\/13\/beyond-diabetes."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2493","article-title":"Cardiac remodelling - part 1: from cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology","volume":"24","author":"Gonz\u00e1lez A","year":"2022","unstructured":"Gonz\u00e1lez A, Richards AM, de Boer RA, et al.. Cardiac remodelling - part 1: from cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022, 24:927-43. 10.1002\/ejhf.2493","journal-title":"Eur J Heart Fail"},{"key":"ref29","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma S","year":"2018","unstructured":"Verma S, McMurray JJ. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018, 61:2108-17.","journal-title":"Diabetologia"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.062769","article-title":"Empagliflozin and left ventricular remodeling in people with heart failure and reduced ejection fraction","volume":"148","author":"Butler J","year":"2023","unstructured":"Butler J, Filippatos G, Jamal W, et al.. Empagliflozin and left ventricular remodeling in people with heart failure and reduced ejection fraction. Circulation. 2023, 148:246-57. 10.1161\/CIRCULATIONAHA.122.062769","journal-title":"Circulation"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/386179-evaluating-the-beneficial-effect-of-empagliflozin-in-reducing-hospitalisation-for-heart-failure-in-patients-with-type-2-diabetes-mellitus-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:22:22Z","timestamp":1762888942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/386179-evaluating-the-beneficial-effect-of-empagliflozin-in-reducing-hospitalisation-for-heart-failure-in-patients-with-type-2-diabetes-mellitus-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.96593","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,11]]}}}